Evidence-Based Medicine Guidelines
SGLT-2 inhibitors and GLP-1 agonists for diabetes and chronic kidney disease
There's more to see -- the rest of this topic is available only to subscribers.
Citation
"SGLT-2 Inhibitors and GLP-1 Agonists for Diabetes and Chronic Kidney Disease." Evidence-Based Medicine Guidelines, Duodecim Medical Publications Limited, 2019. Evidence Central, evidence.unboundmedicine.com/evidence/view/EBMG/1305258/all/SGLT_2_inhibitors_and_GLP_1_agonists_for_diabetes_and_chronic_kidney_disease.
SGLT-2 inhibitors and GLP-1 agonists for diabetes and chronic kidney disease. Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305258/all/SGLT_2_inhibitors_and_GLP_1_agonists_for_diabetes_and_chronic_kidney_disease. Accessed October 5, 2024.
SGLT-2 inhibitors and GLP-1 agonists for diabetes and chronic kidney disease. (2019). In Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited. https://evidence.unboundmedicine.com/evidence/view/EBMG/1305258/all/SGLT_2_inhibitors_and_GLP_1_agonists_for_diabetes_and_chronic_kidney_disease
SGLT-2 Inhibitors and GLP-1 Agonists for Diabetes and Chronic Kidney Disease [Internet]. In: Evidence-Based Medicine Guidelines. Duodecim Medical Publications Limited; 2019. [cited 2024 October 05]. Available from: https://evidence.unboundmedicine.com/evidence/view/EBMG/1305258/all/SGLT_2_inhibitors_and_GLP_1_agonists_for_diabetes_and_chronic_kidney_disease.
* Article titles in AMA citation format should be in sentence-case
TY - ELEC
T1 - SGLT-2 inhibitors and GLP-1 agonists for diabetes and chronic kidney disease
ID - 1305258
BT - Evidence-Based Medicine Guidelines
UR - https://evidence.unboundmedicine.com/evidence/view/EBMG/1305258/all/SGLT_2_inhibitors_and_GLP_1_agonists_for_diabetes_and_chronic_kidney_disease
PB - Duodecim Medical Publications Limited
DB - Evidence Central
DP - Unbound Medicine
ER -
